Wuhan Hiteck Biological Pharma (300683.SZ) announced a预亏,预计 annual net loss of 57 million yuan - 78 million yuan.

Wuhan Hiteck Biological Pharma (300683.SZ) disclosed its performance forecast for 2024, and the company expects the net profit attributable to the Shareholders of the listed company...

Zhitong FinanceJan 23 17:48

Haite Biotech: 2024 performance forecast

SZSIJan 23 17:24 · Announcements

Express News | Wuhan Hiteck Biological Pharma: The company has added the production scope for suppository pharmaceutical production to its pharmaceutical production license.

BreakingsDec 27, 2024 15:51

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13, 2024 21:24

Wuhan Hiteck Biological Pharma (300683.SZ): Injection of rohitidine hydrochloride acetate and ketoconazole injection is expected to be selected for the national Pharmaceutical centralized procurement.

Wuhan Hiteck Biological Pharma (300683.SZ) announced that the company participated in the national organization of pharmaceutical joint procurement office's tenth...

Zhitong FinanceDec 13, 2024 16:38

Express News | Wuhan Hiteck Biological Pharma: Two Pharmaceuticals intended to be selected for national pharmaceutical procurement.

BreakingsDec 13, 2024 16:22